- Home
- NAMS vs APLS Comparison
NAMS vs APLS Comparison
Compare NAMS & APLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NAMS
- APLS
- Stock Information
- Founded
- NAMS 2019
- APLS 2009
- Country
- NAMS Netherlands
- APLS United States
- Employees
- NAMS N/A
- APLS N/A
- Industry
- NAMS Biotechnology: Pharmaceutical Preparations
- APLS Biotechnology: Pharmaceutical Preparations
- Sector
- NAMS Health Care
- APLS Health Care
- Exchange
- NAMS Nasdaq
- APLS Nasdaq
- Market Cap
- NAMS 3.1B
- APLS 3.5B
- IPO Year
- NAMS N/A
- APLS 2017
- Fundamental
- Price
- NAMS $32.86
- APLS $24.92
- Analyst Decision
- NAMS Strong Buy
- APLS Buy
- Analyst Count
- NAMS 9
- APLS 20
- Target Price
- NAMS $41.89
- APLS $33.47
- AVG Volume (30 Days)
- NAMS 974.1K
- APLS 2.3M
- Earning Date
- NAMS 11-05-2025
- APLS 11-04-2025
- Dividend Yield
- NAMS N/A
- APLS N/A
- EPS Growth
- NAMS N/A
- APLS N/A
- EPS
- NAMS N/A
- APLS N/A
- Revenue
- NAMS $64,006,000.00
- APLS $754,649,000.00
- Revenue This Year
- NAMS N/A
- APLS $22.11
- Revenue Next Year
- NAMS $1.67
- APLS N/A
- P/E Ratio
- NAMS N/A
- APLS N/A
- Revenue Growth
- NAMS 762.15
- APLS 20.02
- 52 Week Low
- NAMS $14.06
- APLS $16.10
- 52 Week High
- NAMS $34.62
- APLS $35.72
- Technical
- Relative Strength Index (RSI)
- NAMS 72.18
- APLS 57.85
- Support Level
- NAMS $27.15
- APLS $21.07
- Resistance Level
- NAMS $34.59
- APLS $23.50
- Average True Range (ATR)
- NAMS 1.47
- APLS 0.76
- MACD
- NAMS 0.50
- APLS 0.25
- Stochastic Oscillator
- NAMS 73.37
- APLS 94.98
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.
About APLS Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.